Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?/R, CXCR4, CSF-1R, CD47-SIRP?, Adenosine, STING & Others
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?/R, CXCR4, CSF-1R, CD47-SIRP?, Adenosine, STING & Others
This Competitive Intelligence report about Tumor Microenvironment Modulation via IDO, TGF-?/R, CXCR4, CSF-1R, CD47-SIRP?, Adenosine, STING & Others evaluates as of December 2016 the competitive field of mainly inhibitors and antagonists of substrates, enzymes and receptors involved in the immunosuppressive tumor microenvironment, including
More than 45 new molecular entities modulating the immunosuppressive tumor microenvironment are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further eight molecules are undergoing IND-enabling studies.
The report includes a compilation of currently active projects in research and development of modulators of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of Tumor Microenvironment Modulators. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report about Tumor Microenvironment Modulation via IDO, TGF-?/R, CXCR4, CSF-1R, CD47-SIRP?, Adenosine, STING & Others evaluates as of December 2016 the competitive field of mainly inhibitors and antagonists of substrates, enzymes and receptors involved in the immunosuppressive tumor microenvironment, including
- IDO (Indoleamine 2,3-dioxygenase
- TDO (Tryptophan 2,3 dioxygenase)
- TGF-?/R (Transforming Growth Factor beta/Receptor)
- CXCR4 (Chemokine Receptor Type 4)
- CSF-1R (Colony Stimulating Factor-1 Receptor)
- CD47 – SIRP? (Signal Regulatory Protein Alpha)
- Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
- STING (STimulator of INterferon Genes) Receptor
- Others (e.g. arginase)
More than 45 new molecular entities modulating the immunosuppressive tumor microenvironment are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further eight molecules are undergoing IND-enabling studies.
The report includes a compilation of currently active projects in research and development of modulators of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of Tumor Microenvironment Modulators. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) IDO & TDO INHIBITORS
Epacadostat Studies
Indoximod Studies
Novel IDO Inhibitors
Novel TDO Inhibitors
Dual IDO & TDO Inhibitors
2) TGF-BETA/R INHIBITORS
3) CXCR4 ANTAGONISTS & CXCL12 INHIBITORS
4) CSF-1R ANTAGONISTS & CSF-1R TK INHIBITORS
5) CD47 – SIRP? PATHWAY INHIBITION
6) ADENOSINE PATHWAY
Adenosine A2 Receptor (A2AR) Antagonists
CD73 (AMPase) & CD39 (ATP/ADPase) Inhibitors and Adenosine Degradation
7) STING RECEPTOR STIMULATORS
8) OTHER INHIBITORS OF IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT
9) CORPORATE TUMOR MICROENVIRONMENT MODULATOR R&D PIPELINES
Epacadostat Studies
Indoximod Studies
Novel IDO Inhibitors
Novel TDO Inhibitors
Dual IDO & TDO Inhibitors
2) TGF-BETA/R INHIBITORS
3) CXCR4 ANTAGONISTS & CXCL12 INHIBITORS
4) CSF-1R ANTAGONISTS & CSF-1R TK INHIBITORS
5) CD47 – SIRP? PATHWAY INHIBITION
6) ADENOSINE PATHWAY
Adenosine A2 Receptor (A2AR) Antagonists
CD73 (AMPase) & CD39 (ATP/ADPase) Inhibitors and Adenosine Degradation
7) STING RECEPTOR STIMULATORS
8) OTHER INHIBITORS OF IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT
9) CORPORATE TUMOR MICROENVIRONMENT MODULATOR R&D PIPELINES
